Inflammation: Pharmacology of Aspirin

Introduction/Overview

Aspirin, chemically acetylsalicylic acid, is one of the most widely used therapeutic agents worldwide. Its role in modulating inflammatory pathways has been extensively studied, and it remains a cornerstone in the management of pain, fever, and thrombosis. The clinical relevance of aspirin is underscored by its dual anti‑inflammatory and antiplatelet properties, which have led to broad applications ranging from acute musculoskeletal injury to long‑term cardiovascular prophylaxis. The pharmacological profile of aspirin is intricate, involving irreversible acetylation of cyclooxygenase enzymes and downstream effects on prostaglandin synthesis. Understanding these mechanisms is essential for optimizing therapeutic regimens and minimizing adverse outcomes.

Learning objectives:

• Identify the chemical and pharmacological classification of aspirin and its place among non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Explain the molecular mechanisms by which aspirin exerts anti‑inflammatory effects, including cyclooxygenase inhibition and modulation of eicosanoid pathways.
• Describe the absorption, distribution, metabolism, and excretion (ADME) characteristics that influence dosing and therapeutic monitoring.
• Summarize approved therapeutic indications and commonly employed off‑label uses.
• Recognize common and serious adverse effects, potential drug interactions, and special population considerations.

Classification

Drug Class and Category

Aspirin is classified as a non‑steroidal anti‑inflammatory drug (NSAID). Within the NSAID class, it is distinguished by its irreversible inhibition of cyclooxygenase (COX) enzymes and its unique ability to acetylate serine residues on COX‑1 and COX‑2. It is also categorized as an antiplatelet agent due to its suppression of thromboxane A₂ synthesis in platelets.

Chemical Classification

Structurally, aspirin belongs to the class of salicylate derivatives. Its active moiety, acetylsalicylic acid, consists of a phenolic ring bearing a carboxyl group and an acetylated hydroxyl group. The acetyl group is critical for the drug’s pharmacodynamic activity, enabling covalent modification of the COX active site. The pH-dependent ionization of the carboxyl group influences its gastrointestinal absorption profile.

Mechanism of Action

Pharmacodynamics

Aspirin exerts its anti‑inflammatory effect primarily through irreversible acetylation of the serine 530 residue on COX‑1 and serine 516 on COX‑2. This covalent modification prevents the conversion of arachidonic acid to prostaglandin H₂, thereby reducing downstream prostaglandin E₂ (PGE₂) and thromboxane A₂ (TXA₂) synthesis. The suppression of PGE₂ diminishes vasodilation, capillary permeability, and leukocyte recruitment, key mediators of inflammation. Inhibition of TXA₂, the principal platelet activator, confers antiplatelet activity, reducing aggregation and thrombus formation.

Receptor Interactions

Aspirin’s primary target is the cyclooxygenase enzyme complex; no direct receptor binding is involved. However, the downstream reduction in prostaglandins influences prostanoid receptors (EP, TP) expressed on various cell types, including endothelial cells, smooth muscle cells, and immune cells. By lowering ligand availability, aspirin indirectly modulates receptor-mediated signaling cascades.

Molecular and Cellular Mechanisms

Beyond COX inhibition, aspirin has been implicated in modulating several intracellular pathways. It can activate AMP‑activated protein kinase (AMPK), inhibit nuclear factor‑kappa B (NF‑κB) activation, and promote the production of lipoxins and resolvins, specialized pro‑resolving lipid mediators. These actions contribute to the resolution phase of inflammation, suggesting that aspirin may facilitate the termination of inflammatory responses beyond merely suppressing initiation.

Pharmacokinetics

Absorption

Orally administered aspirin is rapidly absorbed from the stomach and upper small intestine. Its acidic nature leads to a relatively slow dissolution at high gastric pH, but the presence of food can delay, rather than impede, absorption. Peak plasma concentrations are typically reached within 0.5 to 2 hours post‑dose. The bioavailability is high, approximately 75–80% for standard preparations, and is not significantly altered by food intake, although gastric irritation may increase with concomitant ingestion.

Distribution

After absorption, aspirin distributes extensively into body tissues. Its plasma protein binding is moderate, with approximately 30–40% bound to albumin, allowing sufficient free drug to penetrate inflamed tissues. The volume of distribution (Vd) is estimated at 0.5–1.0 L/kg, indicating a moderate extravascular presence. Aspirin readily crosses the placenta and is excreted into breast milk, albeit in low concentrations.

Metabolism

Aspirin undergoes rapid hydrolysis to salicylic acid by non‑specific esterases in the gastrointestinal tract and plasma. Salicylic acid is further conjugated in the liver to form mercapturic acid, glucuronide, and sulfate conjugates, which are collectively eliminated. The parent compound’s half‑life is short (~15–20 minutes), whereas salicylate metabolites exhibit a longer elimination half‑life (~3–4 hours), influencing the duration of pharmacologic effects.

Excretion

Renal excretion is the primary route of elimination. Approximately 70–80% of the administered dose is recovered in the urine as metabolites, with the remainder excreted via biliary routes. The elimination half‑life of salicylate metabolites remains around 3–4 hours, but prolonged dosing can achieve steady‑state concentrations that persist for 24 hours, underpinning its antiplatelet efficacy when administered once daily.

Half‑Life and Dosing Considerations

The pharmacodynamic half‑life of aspirin, defined by the time required for platelet function to recover, exceeds 24 hours due to irreversible COX inhibition. Consequently, a once‑daily dosing schedule is adequate for antiplatelet therapy. For anti‑inflammatory purposes, higher dosing regimens (e.g., 3–4 g/day) are often required, with dosing intervals of 6–8 hours to maintain therapeutic plasma concentrations. Renal impairment may necessitate dose adjustment, since impaired clearance prolongs systemic exposure and increases the risk of toxicity.

Therapeutic Uses/Clinical Applications

Approved Indications

Aspirin is approved for a variety of indications, including:

• Acute pain and fever in adults and children (≥6 years).
• Prevention of coronary artery disease events in high‑risk patients (secondary prevention).
• Primary prevention of cardiovascular events in selected populations with elevated risk.
• Prevention of preeclampsia and eclampsia in high‑risk obstetric patients.
• Management of inflammatory arthropathies at low doses (e.g., rheumatoid arthritis).

Off‑Label and Commonly Employed Uses

Off‑label applications are widespread and include:

• Management of migraine and tension headaches.
• Treatment of acute respiratory distress syndrome (ARDS) via modulation of inflammatory mediators.
• Adjunctive therapy in acute ischemic stroke to reduce platelet aggregation.
• Use in combination with other antithrombotic agents for complex cardiovascular regimens.
• Low‑dose therapy for the prevention of colorectal adenomas in high‑risk patients.

Adverse Effects

Common Side Effects

Aspirin’s most frequent adverse events include gastrointestinal irritation, dyspepsia, and mild gastric mucosal inflammation. Gastric discomfort is dose‑dependent and is exacerbated by high‑dose regimens. Minor bleeding manifestations, such as epistaxis and gum bleeding, may occur due to platelet dysfunction.

Serious/Rare Adverse Reactions

Serious complications, though uncommon, may arise:

• Gastrointestinal ulceration and perforation, particularly in elderly patients or those with pre‑existing ulcers.
• Allergic reactions ranging from urticaria to anaphylaxis in aspirin‑intolerant individuals.
• Reye syndrome in children following viral infections, especially when aspirin is used for fever reduction.
• Bleeding diathesis in patients with coagulopathies or concurrent anticoagulant therapy.

Black Box Warnings

Aspirin carries a black box warning for the risk of gastrointestinal bleeding and ulceration. The warning emphasizes the importance of assessing bleeding risk before initiating therapy, particularly in high‑dose or long‑term regimens. Additionally, the risk of Reye syndrome in children mandates strict avoidance of aspirin for febrile illnesses in this population.

Drug Interactions

Major Drug–Drug Interactions

Aspirin’s antiplatelet effect can be potentiated or attenuated by concomitant medications:

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may compete for COX inhibition, reducing aspirin’s efficacy and increasing gastrointestinal risk.
• Anticoagulants such as warfarin or novel oral anticoagulants (NOACs) can synergistically increase bleeding risk.
• Cytochrome P450 inhibitors or inducers can alter salicylate metabolism, potentially increasing toxicity.
• Selective serotonin reuptake inhibitors (SSRIs) may enhance platelet dysfunction when combined with aspirin.
• Glucocorticoids can exacerbate gastrointestinal mucosal injury when taken with aspirin.

Contraindications

Absolute contraindications include:

• History of aspirin allergy or hypersensitivity reactions.
• Active peptic ulcer disease or significant gastrointestinal bleeding.
• Uncontrolled bleeding disorders or severe thrombocytopenia.
• Concurrent use of anticoagulants in patients with high bleeding risk.
• Pregnancy in the third trimester, unless the benefit outweighs the potential fetal risk.

Special Considerations

Use in Pregnancy and Lactation

During pregnancy, aspirin is generally avoided in the first and second trimesters due to potential teratogenicity and placental effects. Low‑dose aspirin, however, is sometimes employed in the third trimester for preeclampsia prevention, with a typical dose of 81 mg daily. In lactation, salicylate concentrations in breast milk are low, but high doses can pose a risk of salicylate toxicity in infants, warranting caution.

Pediatric Considerations

In children, aspirin is reserved for specific indications such as Kawasaki disease and the prevention of Reye syndrome is contraindicated. Pediatric dosing typically follows weight‑based calculations, with caution exercised in infants and toddlers due to increased susceptibility to gastrointestinal adverse events and salicylate toxicity.

Geriatric Considerations

Older adults exhibit increased sensitivity to aspirin’s antiplatelet effects and a higher baseline risk of gastrointestinal bleeding. Dose reduction, use of gastroprotective agents (e.g., proton pump inhibitors), and careful monitoring for bleeding are recommended. Moreover, renal function decline in the elderly may necessitate dose adjustment to prevent accumulation of salicylate metabolites.

Renal and Hepatic Impairment

In patients with chronic kidney disease, the elimination of aspirin metabolites is reduced, leading to prolonged exposure. Dose reduction or extended dosing intervals may be required. Hepatic impairment can affect salicylate conjugation, potentially increasing systemic exposure; however, mild to moderate liver disease typically does not necessitate major dose changes unless severe dysfunction is present.

Summary/Key Points

Key takeaways for clinical practice:

• Aspirin irreversibly acetylates COX enzymes, reducing prostaglandin and thromboxane synthesis and thereby exerting anti‑inflammatory and antiplatelet effects.
• Its short plasma half‑life contrasts with the prolonged pharmacodynamic effect (>24 h) due to irreversible platelet COX inhibition.
• Standard dosing for antiplatelet therapy is once daily (81 mg), whereas anti‑inflammatory regimens require higher, divided doses (e.g., 3–4 g/day).
• The gastrointestinal system remains the most frequent site of toxicity; concurrent use of gastroprotective agents is advisable for high‑risk patients.
• Drug interactions with other NSAIDs, anticoagulants, SSRIs, and glucocorticoids can potentiate bleeding risk or diminish efficacy; careful medication reconciliation is essential.
• Special populations—pregnant women, pediatric and geriatric patients, and those with renal or hepatic impairment—require individualized dosing and monitoring strategies.
• Clinicians should remain vigilant for signs of Reye syndrome in children and for hypersensitivity reactions in aspirin‑intolerant individuals.

Incorporation of these pharmacologic principles into clinical decision‑making can optimize therapeutic outcomes while mitigating adverse effects associated with aspirin therapy.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.